Akèy › Kansè kanal bil (Kolangyokasinòm) › Texas
Etid klinik pou Kansè kanal bil (Kolangyokasinòm) nan Texas
15 etid pou Kansè kanal bil (Kolangyokasinòm) ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
A Study of PHST001 in Advanced Solid Tumors
- START Center for Cancer Research - Texas, Fort Worth
- MD Anderson Cancer Center, Houston
- NEXT Oncology - Dallas, Irving
- ak 2 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- University of Texas Southwestern Medical Center (Site 104), Dallas
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07265674A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Next Oncology - Austin, Austin
- Next Oncology - Houston, Houston
- Next Oncology - Dallas, Irving
- ak 1 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07488676Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05732831A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
- University of Texas, MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05874414A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- NEXT Dallas, Dallas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07337525A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- MD Anderson Cancer Center, Houston
- Next Oncology-Oncology, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT07169734A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07458347A Study of MGC028 in Participants With Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 27, 2026 · NCT06723236Molecular Epidemiology of Biliary Tree Cancers
- M D Anderson Cancer Center, Houston
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Apr 17, 2026 · NCT05179486A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT05967182SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.